236 
Market Cap
Stock Chart
Biota - 30 day Poll
Recent BLOGS About Biota Add New
Latest Company News
|
Market Wrap: ASX slumps 2.4%
Finance News Network (press release) - May 16, 2012 The Australian share market has fallen to a two month low, dropping 2.4 per cent today following falls on global markets responding to political turmoil in Greece.
|
|
Giving you all the latest in Stock Market Information as it happens...
egoli.com.au - May 16, 2012 For Immediate Release Melbourne, Australia 16 May 2012 Financial update Biota Holdings Limited (ASX:BTA) today provided a financial update on results to 31 March 2012.
|
|
Stocks to watch at close on Wednesday
Sydney Morning Herald - May 16, 2012 AAP Stocks to watch on the Australian stock exchange at close on Wednesday: BHP - BHP BILLITON LTD - down $1.37 - or 4.04 per cent - at $32.49 BHP Billiton chairman Jacques Nasser says the global miner will not spend the $80 billion on growth projects ...
|
|
Biota Announces Inavir(R) Royalty Results for Q312 and Phase III Prevention ...
MarketWatch (press release) - May 11, 2012 MELBOURNE, AUSTRALIA, May 11, 2012 (MARKETWIRE via COMTEX) -- Biota Holdings Limited (asx:BTA) today announced that Daiichi Sankyo Co.
|
|
Mild positive for retailers as Swan budget reaches out to battlers
The Australian - May 9, 2012 AS far as listed stocks go, Wayne Swan's numbers-shuffling effort last night was more compelling for the absence of the "what might have been" measures, rather than the efforts that made their way to the voluminous tome.
|
|
Volatile royalties often bitter pills for biotechs
Brisbane Times - Apr 29, 2012 This much was clear in the wake of last week's column focusing on the market's valuation of cancer therapy developer Prima BioMed (ASX: PRR).
|
|
Volatile royalties often bitter pills for biotechs
BusinessDay.com.au - Apr 29, 2012 This much was clear in the wake of last week's column focusing on the market's valuation of cancer therapy developer Prima BioMed (ASX: PRR).
|
|
Volatile royalties often bitter pills for biotechs
Sydney Morning Herald - Apr 29, 2012 PASSIONS run high in the biotech world. This much was clear in the wake of last week's column focusing on the market's valuation of cancer therapy developer Prima BioMed (ASX: PRR).
|
Website
Videos related to Biota
Company Profile
Biota is a leading anti-infective drug development company, based in Melbourne, Australia. Biota's initial success was the discovery of zanamivir (Relenza), the first-in-class neuraminidase inhibitor for the treatment and prevention of influenza. Zanamivir is licensed to GlaxoSmithKline and marketed as Relenza™. Relenza is used to treat seasonal influenza and is currently being stockpiled by various governments for defence against possible pandemic outbreaks of influenza.
Daiichi Sankyo: for the development of second generation influenza antivirals (called LANI or long-acting inhaled neuraminidase inhibitors) which was approved in Sept. 2010 to market as a drug in Japan. In the USA the same drug is being run through clinical trials with a support of a
BARDA US government contract.
In 2009, Phase IIa clinical trials of its lead human rhinovirus (HRV) drug achieved clinical proof-of-concept. The drug is aimed at prevention and treatment of one of the major causes of the common cold which is also thought to be a major cause of exacerbations in patients with chronic obstructive pulmonary disease and asthma.
Biota also has key partnerships with: Boehringer Ingelheim: where it has a licence and collaboration agreement to develop and commercialise Biota's novel nucleoside analogues, designed to treat hepatitis C virus (HCV) infections and potentially other diseases.
Cash Position Jan 1st 2012: approx. $56.5 million
Net loss for June 2011 year: $11 million
Related companies or competition:
- Tamiflu by Roche
- Gilead Sciences
- NexBio Inc
Partners: GlaxoSmithKline (Relenza), Daichi Sankyo (long acting Relenza - Inavir), Boehringer Ingelheim (HCV), BARDA US government contract
Possible Upcoming Events:
- possible licensing of long-acting Relenza for the US market